There are companies that sell products, and then there are companies that make sure those products actually get into the hands of people who need them. Afaxys, Inc. falls into the second camp, which is the harder one, the one where mission isn’t just a press release line but the business model itself. Founded in 2008 by Ronda K. Dean and Susan Overly, Afaxys was built for one purpose: to make sure public health providers can get reliable, affordable contraceptives without playing supply chain roulette. The name itself is a mashup of affordable and access. It’s not a marketing trick; it’s the operating system.
This month, Afaxys secured $8 million in new funding to push that mission forward. $3 million comes as a program-related investment from the David and Lucile Packard Foundation, their third PRI into Afaxys since 2010, and $5 million as a grant from an anonymous U.S. foundation. That’s not just money; that’s trust built over years of consistent delivery. This capital will move their novel patient-controlled injectable contraceptive, AFX-1001, from R&D toward manufacturing scale-up and first-in-human trials. If it works the way it’s intended, it could change the game for the 19 million U.S. women living in contraceptive deserts.
Afaxys doesn’t operate in the consumer-brand limelight. They run in the institutional lane, where 8,400+ public-health and community clinics, including Planned Parenthood affiliates and Title X-funded centers, depend on their products to serve over 3 million women a year. They are the number one provider of oral and emergency contraceptives in U.S. clinics, holding nearly a quarter of the market in the public health sector. Their model isn’t about selling at scale; it’s about supplying at scale, with stability as the premium feature.
That stability is engineered through two integrated arms: Afaxys Pharma, which delivers FDA-approved branded and generic contraceptives, and Afaxys Group Services, which runs a nationwide group-purchasing organization without membership fees or minimums. Layer in their emapp cloud marketplace for clinic procurement and you’ve got a distribution engine built to eliminate friction between manufacturer and provider.
The leadership is as intentional as the mission. Ronda K. Dean brings decades in pharma and Planned Parenthood leadership; Susan Overly runs operations with the precision of someone who’s been in the trenches since day one. President & Chief Commercial Officer Christian Bloomgren drives market strategy, while Rita O’Connor steers finance and operations with 30 years of experience keeping healthcare companies solvent and scaling.
This isn’t just another funding round. It’s fuel for a company that plays the long game in a space most investors find too messy or politically fraught. Afaxys isn’t just manufacturing products; they’re manufacturing access. And that’s the rare kind of ROI you can measure in both margins and impact.
